News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
Dasatinib could be repurposed to treat pediatric ependymoma – NFCR
NFCR/X
Jan 31, 2025, 07:35

Dasatinib could be repurposed to treat pediatric ependymoma – NFCR

National Foundation for Cancer Research (NFCR) posted on LinkedIn:

“Breakthrough Alert: A leukemia drug may help kids with brain cancer.

New research from NFCR-supported scientist Dr. Rakesh K. Jain at Massachusetts General Hospital Cancer Center suggests that dasatinib (Sprycel), already FDA-approved for leukemia, could be repurposed to treat pediatric ependymoma, a rare and treatment-resistant brain tumor.

By blocking tumor-supporting pathways and reactivating the immune system, dasatinib shows promise in slowing tumor growth and enhancing immune response. This discovery could pave the way for clinical trials and much-needed treatment options for children battling ependymoma.

Read more about this exciting research.”

Dasatinib could be repurposed to treat pediatric ependymoma - NFCR

brain cancer cancer Dasatinib National Foundation for Cancer Research OncoDaily Oncology pediatric ependymoma Rakesh K. Jain
Special Coverage
Blog
Jan 31, 2025, 07:35
Dasatinib could be repurposed to treat pediatric ependymoma - NFCR
Blog
Jan 31, 2025, 07:32
SIOG - Can Remote Patient Monitoring improve Cancer Care for older adults?
Blog
Jan 31, 2025, 07:27
Paolo Tarantino: Outcomes and Treatment Patterns for Stage I HER2-Positive Breast Cancer
Blog
Jan 31, 2025, 07:23
Giuseppe Curigliano: Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer
Blog
Jan 31, 2025, 07:21
Shahrin Ahmed: The key solutions for increasing life-saving cervical cancer screenings
Blog
Jan 31, 2025, 07:20
Elvina Almuradova: Pertuzumab + trastuzumab retreatment to prolong OS in HER2+ metastatic breast cancer
Blog
Jan 31, 2025, 07:17
Catherine Alix-Panabières: Epigenomic Profiling of Liquid Biopsy and Immunotherapy Resistance in Lung Cancer
Blog
Jan 31, 2025, 07:14
Emily Drake: Thrilled to be in Toronto at The Hospital for Sick Children for the ACCESS annual meeting
Blog
Jan 31, 2025, 07:12
Julie S. Torode: Celebrating the Winners of the APCA\TCT 2024 Photography Competition
Blog
Jan 31, 2025, 07:10
Peter Pisters: More than 2,500 MD Anderson Cancer Center teammates at Quarterly Leadership Meeting
Blog
Jan 31, 2025, 07:03
Toufic Kachaamy: Exciting Opportunity for Fellows!
Blog
Jan 31, 2025, 06:59
Francesca D. Ciccarelli: A constitutive interferon-high immunophenotype defines response to IO in colorectal cancer